Cargando…

A multicenter phase II trial of neoadjuvant letrozole plus low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer (JBCRG‐07): therapeutic efficacy and clinical implications of circulating endothelial cells

Neoadjuvant endocrine therapy has been reported to decrease tumor size, which leads to increased breast conservation rates. To improve the clinical response, metronomic chemotherapy with endocrine therapy is a promising strategy. A multicenter phase II single‐arm neoadjuvant trial with letrozole and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ueno, Takayuki, Masuda, Norikazu, Kamigaki, Shunji, Morimoto, Takashi, Akiyama, Futoshi, Kurosumi, Masafumi, Tsuda, Hitoshi, Mikami, Yoshiki, Tanaka, Sunao, Morita, Satoshi, Toi, Masakazu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010720/ https://www.ncbi.nlm.nih.gov/pubmed/29733541 http://dx.doi.org/10.1002/cam4.1516

Ejemplares similares

Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR
por: Ueno, Takayuki, et al.
Publicado: (2019)

Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG
por: Kuroi, Katsumasa, et al.
Publicado: (2014)

Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study
por: Ueno, Takayuki, et al.
Publicado: (2019)

An overview of the Japan Breast Cancer Research Group (JBCRG) activities
por: Ohno, Shinji, et al.
Publicado: (2013)

Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)
por: Aogi, Kenjiro, et al.
Publicado: (2021)

Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)
por: Aogi, Kenjiro, et al.
Publicado: (2021)

Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)
por: Aogi, Kenjiro, et al.
Publicado: (2022)

Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
por: Sato, Nobuaki, et al.
Publicado: (2018)

Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01
por: Yamashiro, Hiroyasu, et al.
Publicado: (2020)

Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study
por: Kawaguchi, Hidetoshi, et al.
Publicado: (2019)

Fulvestrant with or without anti‐HER2 therapy in patients in a postmenopausal hormonal state and with ER‐positive HER2‐positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG‐C06)
por: Masuyama, Misato, et al.
Publicado: (2023)

Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study
por: Hattori, Masaya, et al.
Publicado: (2017)

A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S−1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG‐M01 study)
por: Ishiguro, Hiroshi, et al.
Publicado: (2017)

Correction to: Validation of a nuclear grading system for resected stage I–IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial
por: Tsuda, Hitoshi, et al.
Publicado: (2022)

Validation of a nuclear grading system for resected stage I–IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial
por: Tsuda, Hitoshi, et al.
Publicado: (2022)

A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17)
por: Fukada, Ippei, et al.
Publicado: (2021)

Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study
por: Im, Seock-Ah, et al.
Publicado: (2019)

Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study
por: Takahashi, Masato, et al.
Publicado: (2020)

Correction to: Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study
por: Hattori, Masaya, et al.
Publicado: (2017)

Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR
por: Ueno, Takayuki, et al.
Publicado: (2022)

Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur–uracil with CMF (N·SAS-BC 01 trial and CUBC trial)
por: Ohno, Shinji, et al.
Publicado: (2020)

Palbociclib in combination with letrozole as first‐line treatment for advanced breast cancer: A Japanese phase II study
por: Masuda, Norikazu, et al.
Publicado: (2018)

Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2–positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study)
por: Yamashita, Toshinari, et al.
Publicado: (2020)

Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study)
por: Futamura, Manabu, et al.
Publicado: (2021)

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
por: Sato, Nobuaki, et al.
Publicado: (2019)

A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer
por: Ishiguro, Hiroshi, et al.
Publicado: (2020)

Capecitabine for primary breast cancer
por: Toi, Masakazu, et al.
Publicado: (2017)

Palbociclib as an early-line treatment for Japanese patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: a review of clinical trial and real-world data
por: Masuda, Norikazu, et al.
Publicado: (2021)

Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study
por: Yamamoto, Yutaka, et al.
Publicado: (2020)

Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels
por: Masuda, Norikazu, et al.
Publicado: (2022)

Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer
por: Bazzola, L, et al.
Publicado: (2015)

Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients
por: Mukai, Hirofumi, et al.
Publicado: (2018)

Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)
por: Kim, Jisun, et al.
Publicado: (2014)

Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective
por: Mistry, Rohit, et al.
Publicado: (2018)

Molecular vulnerabilities and therapeutic resistance in hormone receptor positive and HER2 dependent breast cancer tumours
por: Velaga, Ravi, et al.
Publicado: (2022)

Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate
por: Fein, Luis, et al.
Publicado: (2023)

Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2− locally advanced or metastatic breast cancer: a Brazilian private payer perspective
por: Buehler, Anna Maria, et al.
Publicado: (2021)

Correction: Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate
por: Fein, Luis, et al.
Publicado: (2023)

Evaluation of the Interobserver Agreement in the Number of Mitotic Figures Breast Carcinoma as Simulation of Quality Monitoring in the Japan National Surgical Adjuvant Study of Breast Cancer (NSAS‐BC) Protocol
por: Tsuda, Hitoshi, et al.
Publicado: (2000)

Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98
por: Koeberle, Dieter, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_0nu2c6ee7kos77pilf77klrusf